A Phase 1 interventional study of HMPL-306 in Isocitrate Dehydrogenase Gene Mutation, sponsored by Hutchmed. Terminated at 11 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-27.
Sponsored by Hutchmed · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 328 studies in Cholangiocarcinoma with a site in United States — 72 open to participants now, 111 under way, 7 of them phase 3. Cholangiocarcinoma · United States.
Among the 328 studies in Cholangiocarcinoma with a site in United States, this one is the 142nd largest by enrollment of the 279 interventional ones that give a count, is one of 25 that started in 2021, is one of 85 in phase 1, and was the 208th registered.
825 studies on the registry are indexed under Cholangiocarcinoma; 287 are open to participants now.
Browse Cholangiocarcinoma studies →72 of the 328 studies in Cholangiocarcinoma with a site in United States are open now. Recruiting first, the newest first:
Full-Life Technologies UK Limited · Sites in United States, Australia, China
Ages 18+
University of Pennsylvania · Sites in United States
Ages 18+
Ohio State University Comprehensive Cancer Center · Sites in United States
Ages 18+
University of Wisconsin, Madison · Sites in United States
Ages 18+
University of Washington · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 211 Cholangiocarcinoma studies recruiting now, 141 (67%) set no upper age limit and 49 (23%) stop at 75 or younger; 10 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
328 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 127 · Phase 2 142 · Phase 3 24 · Phase 4 1
First in 2001; this study’s year is marked. 25 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 42 is below the median of 50 across 623 interventional studies indexed under Cholangiocarcinoma.
Median enrollment 44 across the 279 interventional studies, 230 across the 45 observational. Of the 190 that completed or were terminated, 94 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
134 of 328 have an industry lead sponsor. The 10 most frequent:
This study is registered under Hutchmed, one of the names counted as HUTCHMED. Under that name alone:
Hutchmed is the lead sponsor of 51 studies on the registry; 12 are open to participants now.
Of its 16 completed or terminated interventional studies of FDA-regulated products, 9 (56%) have results posted.
HUTCHMED has 3 studies filed under Cholangiocarcinoma — fewer than ten, so there is no comparison to draw.
36 of the studies in Cholangiocarcinoma with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05948475Phase 3TransThera Sciences (Nanjing), Inc.Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma | 2026-12 |
| NCT06506955Phase 3Taiho Oncology, Inc.Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy. | 2027-04 |
| NCT05506943Phase 3Compass TherapeuticsA Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002) | 2027-08-31 |
| NCT07265674Phase 3J-Pharma Co., Ltd.A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer | 2027-10 |
| NCT06723236MacroGenicsA Study of MGC028 in Participants With Advanced Solid Tumors | 2026-11 |
Add all 36 to your calendar (.ics) → With an account.
Among the 328 studies in Cholangiocarcinoma with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
An open label single-arm clinical trial to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of HMPL-306 in advanced or metastatic solid tumors with IDH mutation.
HMPL-306 is a dual IDH1/2 inhibitor
This is a phase 1, open-label, multicenter study to evaluate the safety and tolerability of HMPL-306 administered orally in the treatment of subjects with advanced or metastatic solid tumors with IDH mutation. The study consists of 2 parts: Part 1 (dose escalation) and Part 2 (dose expansion). The dose escalation part will determine the MTD/RP2D. The dose expansion part will administer the MTD/RP2D to mIDH-positive solid tumor malignancies including, but not limited to, cholangiocarcinoma, skeletal chondrosarcoma, low-grade glioma, perioperative low-grade glioma
Key Inclusion Criteria:
Subjects are eligible for enrollment into this study if they meet any of the following criteria (NOTE: This is not an exhaustive list):
Key Exclusion Criteria:
Subjects are not eligible for enrollment into this study if they meet any of the following criteria (NOTE: This is not an exhaustive list):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients from each cohort will be administered HMPL-306 orally QD
Drug: HMPL-306
Patients from each cohort will be administered HMPL-306 orally QD at the recommended phase 2 dose
Drug: HMPL-306
Administered orally QD in a 28-day continuous dosing treatment cycle
Part 1: Recommended Phase 2 Dose (RP2D) of HMPL-306
RP2D determination took the following criteria under consideration: determination of maximum tolerated dose (MTD) achieved during the dose escalation part and assessment of safety, pharmacokinetics (PK) and pharmacodynamics (PD). The modified toxicity probability interval-2 design was used to perform dose escalation and planned to determine MTD/RP2D.
Time frame: From the first dose of study drug (Day 1) up to Day 28 of Cycle 1
Part 1: Number of Patients With Dose-limiting Toxicities (DLTs)
DLT:occurrence of any of following treatment-emergent adverse events (TEAEs) during DLT assessment window unless clearly unrelated to study drug/judged by investigator as not clinically significant: 1. Non-hematologic:TEAEs Grade \>=4, Grade 3 except those which recovered to Grade \<=1 within 3 days after supportive therapy administered for nausea,vomiting,diarrhea,constipation,fatigue,electrolyte imbalance;Grade 3 hypothyroidism, adrenal gland or pituitary insufficiency, and inflammatory reactions at tumor site \& Grade 3 hypertension downgraded to Grade \<=1 within 1 week with appropriate supportive therapy. 2. Hematologic:Grade \>=3 febrile neutropenia;Grade 4 neutropenia or thrombocytopenia;Grade 3 thrombocytopenia with clinically significant bleeding in addition to that requiring transfusion;Grade 4 anemia requiring a dose delay of \>=14 days. 3. Any life-threatening complication/abnormality not covered in National Cancer Institute Common Terminology Criteria for AEs version(v) 5.0.
Time frame: From the first dose of study drug (Day 1) up to Day 28 of Cycle 1
Parts 1 and 2: Number of Patients With Treatment-Emergent Adverse Events and Treatment-Emergent Serious Adverse Events (TESAEs)
AE:unfavorable,unintended sign,symptom or disease temporally associated with use of study drug or other protocol-imposed drug, whether or not considered drug related. SAE:AE that resulted in death, was life threatening, inpatient hospitalization/prolongation of existing hospitalization, persistent/significant incapacity or substantial disruption of ability to conduct normal life functions, congenital anomaly/birth defect, important medical event that jeopardized patient and required medical/surgical intervention to prevent above outcome or signs, symptoms or clinical sequelae of suspected overdose of either study drug or a concomitant medication. TEAE:AE with onset on/after start of study drug until 30 days after last dose or prior to start of subsequent anti-tumor therapy, or AE with onset before start of study drug but worsened in severity after study drug administration or beyond 30 days after last dose or after start of subsequent anti-tumor therapy and treatment-related SAEs.
Time frame: From the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 43 months for Part 1
Parts 1 and 2: Objective Response Rate (ORR)
ORR by response evaluation criteria in solid tumors (RECIST) v1.1 was defined as the percentage of patients with confirmed best overall response (BOR) of complete response (CR) or partial response (PR) as determined by the investigator. CR: disappearance of all target lesions. PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. ORR by response assessment in neuro-oncology criteria (RANO) was defined as the percentage of patients with a BOR of CR or PR or minor response (MR) as determined by the investigator using RANO criteria mentioned in protocol for glioma patients.
Time frame: Tumor assessments performed every 8 weeks (+/-1 week) from Cycle 1 Day 1 for the first 24 weeks and every 12 weeks (+/-2 weeks) thereafter until end of treatment or end of efficacy follow-up period, approximately 47 months for Part 1
Parts 1 and 2: Disease Control Rate (DCR)
DCR by RECIST v1.1 was defined as percentage of patients with BOR of CR, PR, or stable disease (SD) lasting at least 7 weeks as determined by investigator.CR: disappearance of all target lesions.PR: at least a 30% decrease in sum of diameters of target lesions, taking as reference baseline sum of diameters.SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for Pd, taking as reference the smallest sum on study. Pd: at least 20% increase in sum of diameters of target lesions, taking as reference smallest sum on study (nadir), including baseline. In addition to relative increase of 20%, sum must also demonstrate an absolute increase of at least 5 millimeters (mm). The appearance of 1 or more new lesions was also considered progression. DCR by RANO was defined as percentage of patients with BOR of CR, PR, MR, or SD lasting at least 7 weeks as determined by investigator using RANO criteria mentioned in protocol for glioma patients.
Time frame: Tumor assessments performed every 8 weeks (+/-1 week) from Cycle 1 Day 1 for the first 24 weeks and every 12 weeks (+/-2 weeks) thereafter until end of treatment or end of efficacy follow-up period, approximately 47 months for Part 1
Parts 1 and 2: Duration of Response (DoR)
DoR by RECIST v1.1 was defined as the time from the first occurrence of confirmed PR or confirmed CR until Pd or death, whichever came first. CR: disappearance of all target lesions. PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. Pd: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (nadir), including baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered progression. DoR by RANO was defined as the time from the first occurrence of CR or PR or MR using RANO criteria mentioned in protocol for glioma patients, until disease progression or death, whichever comes first. Due to early study termination, Part 2 was never initiated.
Time frame: Tumor assessments performed every 8 weeks (+/-1 week) from Cycle 1 Day 1 for the first 24 weeks and every 12 weeks (+/-2 weeks) thereafter until end of treatment or end of efficacy follow-up period, approximately 47 months for Part 1
Parts 1 and 2: Time to Response (TTR)
TTR by RECIST v1.1 was defined as the time from start of study treatment until the date of first documented objective response, either confirmed CR or confirmed PR (whichever status was recorded first). CR: disappearance of all target lesions. PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. TTR by RANO was defined as the time from start of study treatment until the date of first documented objective response, either CR or PR or MR (whichever status was recorded first) using RANO criteria mentioned in protocol for glioma patients. Due to early study termination, Part 2 was never initiated.
Time frame: Tumor assessments performed every 8 weeks (+/-1 week) from Cycle 1 Day 1 for the first 24 weeks and every 12 weeks (+/-2 weeks) thereafter until end of treatment or end of efficacy follow-up period, approximately 47 months for Part 1
Parts 1 and 2: Progression-free Survival (PFS)
PFS was defined as the time from the date of first administration of study drug until the first radiographic documentation of objective progression as assessed by investigator using RECIST v1.1 or RANO criteria for glioma patients, or death from any cause. As per RECIST v1.1: Pd: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (nadir), including baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of 1 or more new lesions was also considered progression. Criteria for RANO as mentioned in protocol.
Time frame: Tumor assessments performed every 8 weeks (+/-1 week) from Cycle 1 Day 1 for the first 24 weeks and every 12 weeks (+/-2 weeks) thereafter until end of treatment or end of efficacy follow-up period, approximately 47 months for Part 1
Parts 1 and 2: Maximum Observed Plasma Concentration (Cmax) of HMPL-306
Blood samples were collected at the specified timepoints to determine Cmax of HMPL-306.
Time frame: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8 and 24 hours post-dose on Day 1 of Cycles 1 and 2 for Part 1
Parts 1 and 2: Time to Peak Plasma Concentration (Tmax) of HMPL-306
Blood samples were collected at the specified timepoints to determine Tmax of HMPL-306.
Time frame: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8 and 24 hours post-dose on Day 1 of Cycles 1 and 2 for Part 1
Parts 1 and 2: Area Under the Plasma Concentration-Time Curve From 0 to 24 Hours (AUC0-24) of HMPL-306
Blood samples were collected at the specified timepoints to determine AUC0-24 of HMPL-306.
Time frame: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8 and 24 hours post-dose on Day 1 of Cycles 1 and 2 for Part 1
Parts 1 and 2: Maximum Inhibition Rate of Plasma 2-Hydroxyglutaric Acid (2-HG)
Blood samples were collected at the specified timepoints to determine plasma concentrations of 2-HG which was a PD marker. The maximum inhibition rate of 2-HG for patients in different dose groups is presented.
Time frame: From screening (Day -28) until end of treatment, approximately 42 months for Part 1
This Phase 1, open-label study was conducted in patients with locally advanced or metastatic solid tumors with isocitrate dehydrogenase (IDH) mutations and consisted of dose escalation part (Part 1) and dose expansion part (Part 2).
| Milestone | Part 1: Cohort-1: HMPL-306 50 mg | Part 1: Cohort-2: HMPL-306 100 mg | Part 1: Cohort-3: HMPL-306 150 mg | Part 1: Cohort-4: HMPL-306 200 mg | Part 1: Cohort-5: HMPL-306 250 mg | Part 1: Cohort-6: HMPL-306 300 mg | Part 1: Cohort-7: HMPL-306 350 mg | Part 1: Cohort-8: HMPL-306 400 mg |
|---|---|---|---|---|---|---|---|---|
| Started | 3 | 3 | 5 | 12 | 6 | 4 | 4 | 5 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 3 | 3 | 5 | 12 | 6 | 4 | 4 | 5 |
| Withdrew: Other | 3 | 3 | 3 | 11 | 3 | 4 | 3 | 5 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 0 |
| Withdrew: Death | 0 | 0 | 1 | 1 | 2 | 0 | 0 | 0 |
RP2D determination took the following criteria under consideration: determination of maximum tolerated dose (MTD) achieved during the dose escalation part and assessment of safety, pharmacokinetics (PK) and pharmacodynamics (PD). The modified toxicity probability interval-2 design was used to perform dose escalation and planned to determine MTD/RP2D.
| milligrams | Part 1: Cohorts-1 to 8: HMPL-306 |
|---|---|
| Part 1: Recommended Phase 2 Dose (RP2D) of HMPL-306 | NA |
DLT:occurrence of any of following treatment-emergent adverse events (TEAEs) during DLT assessment window unless clearly unrelated to study drug/judged by investigator as not clinically significant: 1. Non-hematologic:TEAEs Grade \>=4, Grade 3 except those which recovered to Grade \<=1 within 3 days after supportive therapy administered for nausea,vomiting,diarrhea,constipation,fatigue,electrolyte imbalance;Grade 3 hypothyroidism, adrenal gland or pituitary insufficiency, and inflammatory reactions at tumor site \& Grade 3 hypertension downgraded to Grade \<=1 within 1 week with appropriate supportive therapy. 2. Hematologic:Grade \>=3 febrile neutropenia;Grade 4 neutropenia or thrombocytopenia;Grade 3 thrombocytopenia with clinically significant bleeding in addition to that requiring transfusion;Grade 4 anemia requiring a dose delay of \>=14 days. 3. Any life-threatening complication/abnormality not covered in National Cancer Institute Common Terminology Criteria for AEs version(v) 5.0.
| Participants | Part 1: Cohort-1: HMPL-306 50 mg | Part 1: Cohort-2: HMPL-306 100 mg | Part 1: Cohort-3: HMPL-306 150 mg | Part 1: Cohort-4: HMPL-306 200 mg | Part 1: Cohort-5: HMPL-306 250 mg | Part 1: Cohort-6: HMPL-306 300 mg | Part 1: Cohort-7: HMPL-306 350 mg | Part 1: Cohort-8: HMPL-306 400 mg |
|---|---|---|---|---|---|---|---|---|
| Part 1: Number of Patients With Dose-limiting Toxicities (DLTs) | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
AE:unfavorable,unintended sign,symptom or disease temporally associated with use of study drug or other protocol-imposed drug, whether or not considered drug related. SAE:AE that resulted in death, was life threatening, inpatient hospitalization/prolongation of existing hospitalization, persistent/significant incapacity or substantial disruption of ability to conduct normal life functions, congenital anomaly/birth defect, important medical event that jeopardized patient and required medical/surgical intervention to prevent above outcome or signs, symptoms or clinical sequelae of suspected overdose of either study drug or a concomitant medication. TEAE:AE with onset on/after start of study drug until 30 days after last dose or prior to start of subsequent anti-tumor therapy, or AE with onset before start of study drug but worsened in severity after study drug administration or beyond 30 days after last dose or after start of subsequent anti-tumor therapy and treatment-related SAEs.
| Participants | Part 1: Cohort-1: HMPL-306 50 mg | Part 1: Cohort-2: HMPL-306 100 mg | Part 1: Cohort-3: HMPL-306 150 mg | Part 1: Cohort-4: HMPL-306 200 mg | Part 1: Cohort-5: HMPL-306 250 mg | Part 1: Cohort-6: HMPL-306 300 mg | Part 1: Cohort-7: HMPL-306 350 mg | Part 1: Cohort-8: HMPL-306 400 mg |
|---|---|---|---|---|---|---|---|---|
| TEAEs | 3 | 3 | 5 | 11 | 5 | 4 | 4 | 5 |
| TESAEs | 1 | 1 | 2 | 1 | 0 | 2 | 1 | 1 |
ORR by response evaluation criteria in solid tumors (RECIST) v1.1 was defined as the percentage of patients with confirmed best overall response (BOR) of complete response (CR) or partial response (PR) as determined by the investigator. CR: disappearance of all target lesions. PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. ORR by response assessment in neuro-oncology criteria (RANO) was defined as the percentage of patients with a BOR of CR or PR or minor response (MR) as determined by the investigator using RANO criteria mentioned in protocol for glioma patients.
| percentage of patients | Part 1: Cohort-1: HMPL-306 50 mg | Part 1: Cohort-2: HMPL-306 100 mg | Part 1: Cohort-3: HMPL-306 150 mg | Part 1: Cohort-4: HMPL-306 200 mg | Part 1: Cohort-5: HMPL-306 250 mg | Part 1: Cohort-6: HMPL-306 300 mg | Part 1: Cohort-7: HMPL-306 350 mg | Part 1: Cohort-8: HMPL-306 400 mg |
|---|---|---|---|---|---|---|---|---|
| Parts 1 and 2: Objective Response Rate (ORR) | 0 (0.0 to 70.8) | 33.3 (0.8 to 90.6) | 0 (0.0 to 60.2) | 8.3 (0.2 to 38.5) | 20.0 (0.5 to 71.6) | 0 (0.0 to 60.2) | 0 (0.0 to 84.2) | 0 (0 to 52.2) |
DCR by RECIST v1.1 was defined as percentage of patients with BOR of CR, PR, or stable disease (SD) lasting at least 7 weeks as determined by investigator.CR: disappearance of all target lesions.PR: at least a 30% decrease in sum of diameters of target lesions, taking as reference baseline sum of diameters.SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for Pd, taking as reference the smallest sum on study. Pd: at least 20% increase in sum of diameters of target lesions, taking as reference smallest sum on study (nadir), including baseline. In addition to relative increase of 20%, sum must also demonstrate an absolute increase of at least 5 millimeters (mm). The appearance of 1 or more new lesions was also considered progression. DCR by RANO was defined as percentage of patients with BOR of CR, PR, MR, or SD lasting at least 7 weeks as determined by investigator using RANO criteria mentioned in protocol for glioma patients.
| percentage of patients | Part 1: Cohort-1: HMPL-306 50 mg | Part 1: Cohort-2: HMPL-306 100 mg | Part 1: Cohort-3: HMPL-306 150 mg | Part 1: Cohort-4: HMPL-306 200 mg | Part 1: Cohort-5: HMPL-306 250 mg | Part 1: Cohort-6: HMPL-306 300 mg | Part 1: Cohort-7: HMPL-306 350 mg | Part 1: Cohort-8: HMPL-306 400 mg |
|---|---|---|---|---|---|---|---|---|
| Parts 1 and 2: Disease Control Rate (DCR) | 0 (0.0 to 70.8) | 66.7 (9.4 to 99.2) | 50.0 (6.8 to 93.2) | 66.7 (34.9 to 90.1) | 60.0 (14.7 to 94.7) | 75.0 (19.4 to 99.4) | 50.0 (1.3 to 98.7) | 40.0 (5.3 to 85.3) |
DoR by RECIST v1.1 was defined as the time from the first occurrence of confirmed PR or confirmed CR until Pd or death, whichever came first. CR: disappearance of all target lesions. PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. Pd: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (nadir), including baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered progression. DoR by RANO was defined as the time from the first occurrence of CR or PR or MR using RANO criteria mentioned in protocol for glioma patients, until disease progression or death, whichever comes first. Due to early study termination, Part 2 was never initiated.
| months | Part 1: Cohort-1: HMPL-306 50 mg | Part 1: Cohort-2: HMPL-306 100 mg | Part 1: Cohort-3: HMPL-306 150 mg | Part 1: Cohort-4: HMPL-306 200 mg | Part 1: Cohort-5: HMPL-306 250 mg | Part 1: Cohort-6: HMPL-306 300 mg | Part 1: Cohort-7: HMPL-306 350 mg | Part 1: Cohort-8: HMPL-306 400 mg |
|---|---|---|---|---|---|---|---|---|
| Parts 1 and 2: Duration of Response (DoR) | — | NA (NA to NA) | — | 16.8 (NA to NA) | NA (NA to NA) | — | — | — |
TTR by RECIST v1.1 was defined as the time from start of study treatment until the date of first documented objective response, either confirmed CR or confirmed PR (whichever status was recorded first). CR: disappearance of all target lesions. PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. TTR by RANO was defined as the time from start of study treatment until the date of first documented objective response, either CR or PR or MR (whichever status was recorded first) using RANO criteria mentioned in protocol for glioma patients. Due to early study termination, Part 2 was never initiated.
| months | Part 1: Cohort-1: HMPL-306 50 mg | Part 1: Cohort-2: HMPL-306 100 mg | Part 1: Cohort-3: HMPL-306 150 mg | Part 1: Cohort-4: HMPL-306 200 mg | Part 1: Cohort-5: HMPL-306 250 mg | Part 1: Cohort-6: HMPL-306 300 mg | Part 1: Cohort-7: HMPL-306 350 mg | Part 1: Cohort-8: HMPL-306 400 mg |
|---|---|---|---|---|---|---|---|---|
| Parts 1 and 2: Time to Response (TTR) | — | 2.1 (NA to NA) | — | 3.7 (NA to NA) | 22.1 (NA to NA) | — | — | — |
PFS was defined as the time from the date of first administration of study drug until the first radiographic documentation of objective progression as assessed by investigator using RECIST v1.1 or RANO criteria for glioma patients, or death from any cause. As per RECIST v1.1: Pd: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (nadir), including baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of 1 or more new lesions was also considered progression. Criteria for RANO as mentioned in protocol.
| months | Part 1: Cohort-1: HMPL-306 50 mg | Part 1: Cohort-2: HMPL-306 100 mg | Part 1: Cohort-3: HMPL-306 150 mg | Part 1: Cohort-4: HMPL-306 200 mg | Part 1: Cohort-5: HMPL-306 250 mg | Part 1: Cohort-6: HMPL-306 300 mg | Part 1: Cohort-7: HMPL-306 350 mg | Part 1: Cohort-8: HMPL-306 400 mg |
|---|---|---|---|---|---|---|---|---|
| Parts 1 and 2: Progression-free Survival (PFS) | 1.9 (1.8 to NA) | 5.5 (1.8 to NA) | 2.7 (0.8 to NA) | 5.6 (1.7 to 12.9) | 3.7 (1.7 to NA) | 8.3 (1.6 to NA) | NA (NA to NA) | 1.9 (0.6 to NA) |
Blood samples were collected at the specified timepoints to determine Cmax of HMPL-306.
| nanogram/milliliter (ng/mL) | Part 1: Cohort-1: HMPL-306 50 mg | Part 1: Cohort-2: HMPL-306 100 mg | Part 1: Cohort-3: HMPL-306 150 mg | Part 1: Cohort-4: HMPL-306 200 mg | Part 1: Cohort-5: HMPL-306 250 mg | Part 1: Cohort-6: HMPL-306 300 mg | Part 1: Cohort-7: HMPL-306 350 mg | Part 1: Cohort-8: HMPL-306 400 mg |
|---|---|---|---|---|---|---|---|---|
| Cycle 1 Day 1 | 181 ± 17.5 | 487 ± 35.1 | 365 ± 26.6 | 550 ± 43.2 | 596 ± 35.6 | 645 ± 38.9 | 670 ± 51.9 | 885 ± 45.7 |
| Cycle 2 Day 1 | 414 ± 34.3 | 891 ± 30.1 | 1025 ± 6.0 | 1633 ± 26.0 | 1721 ± 15.5 | 1943 ± 71.7 | 1758 ± 61.2 | 3665 ± 36.1 |
Blood samples were collected at the specified timepoints to determine Tmax of HMPL-306.
| hour | Part 1: Cohort-1: HMPL-306 50 mg | Part 1: Cohort-2: HMPL-306 100 mg | Part 1: Cohort-3: HMPL-306 150 mg | Part 1: Cohort-4: HMPL-306 200 mg | Part 1: Cohort-5: HMPL-306 250 mg | Part 1: Cohort-6: HMPL-306 300 mg | Part 1: Cohort-7: HMPL-306 350 mg | Part 1: Cohort-8: HMPL-306 400 mg |
|---|---|---|---|---|---|---|---|---|
| Cycle 1 Day 1 | 2.17 (2.02 to 2.17) | 1.97 (1.00 to 3.08) | 2.12 (1.15 to 3.02) | 2.55 (1.00 to 4.22) | 2.20 (1.07 to 3.02) | 2.92 (2.03 to 6.00) | 2.92 (2.15 to 3.00) | 2.90 (2.00 to 3.02) |
| Cycle 2 Day 1 | 2.12 (2.10 to 2.13) | 1.10 (1.00 to 4.17) | 2.05 (1.08 to 4.08) | 1.17 (0.533 to 3.15) | 2.97 (0.983 to 3.75) | 2.00 (1.03 to 3.00) | 2.00 (1.00 to 3.00) | 1.96 (1.03 to 3.05) |
Blood samples were collected at the specified timepoints to determine AUC0-24 of HMPL-306.
| hour*ng/mL | Part 1: Cohort-1: HMPL-306 50 mg | Part 1: Cohort-2: HMPL-306 100 mg | Part 1: Cohort-3: HMPL-306 150 mg | Part 1: Cohort-4: HMPL-306 200 mg | Part 1: Cohort-5: HMPL-306 250 mg | Part 1: Cohort-6: HMPL-306 300 mg | Part 1: Cohort-7: HMPL-306 350 mg | Part 1: Cohort-8: HMPL-306 400 mg |
|---|---|---|---|---|---|---|---|---|
| Cycle 1 Day 1 | 1625 ± 19.5 | 2894 ± 31.4 | 3084 ± 21.3 | 5007 ± 36.0 | 5045 ± 33.9 | 8315 ± 52.8 | 7556 ± 24.5 | 9712 ± 37.5 |
| Cycle 2 Day 1 | 7033 ± 65.9 | 12907 ± 30.7 | 16710 ± 12.3 | 27427 ± 26.2 | 26616 ± 24.5 | 38461 ± 64.6 | 28342 ± 36.9 | 58900 ± 48.5 |
Blood samples were collected at the specified timepoints to determine plasma concentrations of 2-HG which was a PD marker. The maximum inhibition rate of 2-HG for patients in different dose groups is presented.
| percentage of inhibition | Part 1: Cohort-1: HMPL-306 50 mg | Part 1: Cohort-2: HMPL-306 100 mg | Part 1: Cohort-3: HMPL-306 150 mg | Part 1: Cohort-4: HMPL-306 200 mg | Part 1: Cohort-5: HMPL-306 250 mg | Part 1: Cohort-6: HMPL-306 300 mg | Part 1: Cohort-7: HMPL-306 350 mg | Part 1: Cohort-8: HMPL-306 400 mg |
|---|---|---|---|---|---|---|---|---|
| Parts 1 and 2: Maximum Inhibition Rate of Plasma 2-Hydroxyglutaric Acid (2-HG) | 39.04 ± 17.73 | 69.15 ± 3.52 | 76.93 ± 17.17 | 80.79 ± 12.54 | 53.83 ± 6.68 | 95.74 ± 4.45 | 83.22 ± 11.03 | 87.33 ± 6.29 |
Collected over Adverse events were collected from the from the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 43 months for Part 1. All-cause mortality (deaths) was collected from the first dose of study drug (Day 1) up to end of follow-up, approximately 47 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: Cohort-1: HMPL-306 50 mg | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| Part 1: Cohort-2: HMPL-306 100 mg | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| Part 1: Cohort-3: HMPL-306 150 mg | 1/5 (20%) | 2/5 (40%) | 4/5 (80%) |
| Part 1: Cohort-4: HMPL-306 200 mg | 1/12 (8.3%) | 1/12 (8.3%) | 11/12 (91.7%) |
| Part 1: Cohort-5: HMPL-306 250 mg | 2/6 (33.3%) | 0/6 (0%) | 5/6 (83.3%) |
| Part 1: Cohort-6: HMPL-306 300 mg | 0/4 (0%) | 2/4 (50%) | 4/4 (100%) |
| Part 1: Cohort-7: HMPL-306 350 mg | 0/4 (0%) | 1/4 (25%) | 4/4 (100%) |
| Part 1: Cohort-8: HMPL-306 400 mg | 0/5 (0%) | 1/5 (20%) | 5/5 (100%) |
| Event | Part 1: Cohort-1: HMPL-306 50 mg | Part 1: Cohort-2: HMPL-306 100 mg | Part 1: Cohort-3: HMPL-306 150 mg | Part 1: Cohort-4: HMPL-306 200 mg | Part 1: Cohort-5: HMPL-306 250 mg | Part 1: Cohort-6: HMPL-306 300 mg | Part 1: Cohort-7: HMPL-306 350 mg | Part 1: Cohort-8: HMPL-306 400 mg |
|---|---|---|---|---|---|---|---|---|
| BacteraemiaInfections and infestations | 1/3 | 0/3 | 0/5 | 0/12 | — | 0/4 | 0/4 | 0/5 |
| Device related infectionInfections and infestations | 1/3 | 0/3 | 0/5 | 0/12 | — | 0/4 | 0/4 | 0/5 |
| Wound infectionInfections and infestations | 0/3 | 1/3 | 0/5 | 0/12 | — | 0/4 | 0/4 | 0/5 |
| Urinary tract infectionInfections and infestations | 0/3 | 0/3 | 0/5 | 0/12 | — | 1/4 | 0/4 | 0/5 |
| EpilepsyNervous system disorders | 0/3 | 0/3 | 1/5 | 0/12 | — | 1/4 | 0/4 | 0/5 |
| PyrexiaGeneral disorders | 0/3 | 0/3 | 0/5 | 0/12 | — | 0/4 | 1/4 | 0/5 |
| Depressed level of consciousnessNervous system disorders | 0/3 | 0/3 | 0/5 | 0/12 | — | 0/4 | 0/4 | 1/5 |
| Neoplasm swellingNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/3 | 0/3 | 0/5 | 0/12 | — | 0/4 | 0/4 | 1/5 |
| Tumour haemorrhageNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/3 | 0/3 | 1/5 | 0/12 | — | 0/4 | 0/4 | 0/5 |
| Biliary obstructionHepatobiliary disorders | 0/3 | 0/3 | 1/5 | 0/12 | — | 0/4 | 0/4 | 0/5 |
| Event | Part 1: Cohort-1: HMPL-306 50 mg | Part 1: Cohort-2: HMPL-306 100 mg | Part 1: Cohort-3: HMPL-306 150 mg | Part 1: Cohort-4: HMPL-306 200 mg | Part 1: Cohort-5: HMPL-306 250 mg | Part 1: Cohort-6: HMPL-306 300 mg | Part 1: Cohort-7: HMPL-306 350 mg | Part 1: Cohort-8: HMPL-306 400 mg |
|---|---|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 0/3 | 1/3 | 1/5 | 1/12 | 1/6 | 2/4 | 2/4 | 0/5 |
| VomitingGastrointestinal disorders | 0/3 | 1/3 | 0/5 | 0/12 | 1/6 | 2/4 | 1/4 | 0/5 |
| Gamma-glutamyltransferase increasedInvestigations | 0/3 | 0/3 | 0/5 | 0/12 | 0/6 | 0/4 | 2/4 | 0/5 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 0/3 | 0/3 | 0/5 | 0/12 | 0/6 | 2/4 | 0/4 | 0/5 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/3 | 0/3 | 0/5 | 0/12 | 0/6 | 2/4 | 0/4 | 0/5 |
| Decreased appetiteMetabolism and nutrition disorders | 0/3 | 0/3 | 1/5 | 0/12 | 1/6 | 1/4 | 1/4 | 2/5 |
| HeadacheNervous system disorders | 0/3 | 0/3 | 0/5 | 2/12 | 0/6 | 1/4 | 0/4 | 2/5 |
| AstheniaGeneral disorders | 0/3 | 0/3 | 0/5 | 3/12 | 0/6 | 1/4 | 1/4 | 2/5 |
| InsomniaPsychiatric disorders | 0/3 | 0/3 | 0/5 | 0/12 | 1/6 | 0/4 | 0/4 | 2/5 |
| DiarrhoeaGastrointestinal disorders | 0/3 | 0/3 | 0/5 | 2/12 | 2/6 | 1/4 | 1/4 | 1/5 |
The safety analysis set included all enrolled patients who received at least 1 dose of study drug.
| Age, Continuous(years) | Part 1: Cohort-1: HMPL-306 50 mg | Part 1: Cohort-2: HMPL-306 100 mg | Part 1: Cohort-3: HMPL-306 150 mg | Part 1: Cohort-4: HMPL-306 200 mg | Part 1: Cohort-5: HMPL-306 250 mg | Part 1: Cohort-6: HMPL-306 300 mg | Part 1: Cohort-7: HMPL-306 350 mg | Part 1: Cohort-8: HMPL-306 400 mg | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 48.3 ± 19.04 | 54.0 ± 9.64 | 55.4 ± 10.69 | 53.0 ± 19.29 | 52.3 ± 9.71 | 54.8 ± 11.53 | 57.3 ± 5.56 | 53.0 ± 16.32 | 53.5 ± 13.67 |
| Sex: Female, Male(Participants) | Part 1: Cohort-1: HMPL-306 50 mg | Part 1: Cohort-2: HMPL-306 100 mg | Part 1: Cohort-3: HMPL-306 150 mg | Part 1: Cohort-4: HMPL-306 200 mg | Part 1: Cohort-5: HMPL-306 250 mg | Part 1: Cohort-6: HMPL-306 300 mg | Part 1: Cohort-7: HMPL-306 350 mg | Part 1: Cohort-8: HMPL-306 400 mg | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 2 | 2 | 0 | 5 | 3 | 2 | 0 | 3 | 17 |
| Male | 1 | 1 | 5 | 7 | 3 | 2 | 4 | 2 | 25 |
| Ethnicity (NIH/OMB)(Participants) | Part 1: Cohort-1: HMPL-306 50 mg | Part 1: Cohort-2: HMPL-306 100 mg | Part 1: Cohort-3: HMPL-306 150 mg | Part 1: Cohort-4: HMPL-306 200 mg | Part 1: Cohort-5: HMPL-306 250 mg | Part 1: Cohort-6: HMPL-306 300 mg | Part 1: Cohort-7: HMPL-306 350 mg | Part 1: Cohort-8: HMPL-306 400 mg | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 3 | 1 | 0 | 0 | 0 | 4 |
| Not Hispanic or Latino | 2 | 3 | 5 | 9 | 5 | 4 | 4 | 5 | 37 |
| Unknown or Not Reported | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Race/Ethnicity, Customized(Participants) | Part 1: Cohort-1: HMPL-306 50 mg | Part 1: Cohort-2: HMPL-306 100 mg | Part 1: Cohort-3: HMPL-306 150 mg | Part 1: Cohort-4: HMPL-306 200 mg | Part 1: Cohort-5: HMPL-306 250 mg | Part 1: Cohort-6: HMPL-306 300 mg | Part 1: Cohort-7: HMPL-306 350 mg | Part 1: Cohort-8: HMPL-306 400 mg | Total |
|---|---|---|---|---|---|---|---|---|---|
| Asian | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Black or African American | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| White | 2 | 2 | 4 | 11 | 6 | 4 | 4 | 5 | 38 |
| Not Reported | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Other | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Feb 2021 to primary completion in Feb 2025, 47 months.
Results were first posted in Mar 2026, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ranosidenib